{"filings":[{"id":815876,"accession_number":"0001628280-26-040048","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2026-06-03T12:03:31+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLife Solutions issues investor presentation for Jefferies conference; no material updates disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated June 3, 2026, furnished as Exhibit 99.1.","Available on company website and used at Jefferies Global Healthcare Conference.","No new financial guidance, business updates, or key metrics provided in the filing.","Presentation cover cites 'Industry-Leading Solutions for Cell-Based Therapies'."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99132,"accession_number":"0001628280-26-032123","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Solutions Q1 revenue up 25% YoY to $27.5M; net income $1.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $27.5M, +25% YoY from $22.1M; GAAP net income $1.2M vs $0.3M in Q1 2025.","Non-GAAP adjusted EBITDA $6.2M (22% of revenue) vs $5.4M (24% of revenue) in Q1 2025.","GAAP EPS $0.02; GAAP gross margin 64% (down from 67% YoY); adjusted gross margin 64% (down from 68%).","Reiterated FY 2026 guidance: revenue $112.5-115.0M, mid-60% gross margin, full-year net income.","Biopreservation media embedded in 17 commercial CGTs and ~250 ongoing U.S. clinical trials (70% share)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":27500000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114975,"accession_number":"0001628280-26-013277","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLife Solutions issues routine investor presentation; no material news disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Investor presentation released on March 2, 2026, highlights cell-based therapy solutions.","Presentation available at company's investor relations website.","No financial results, guidance changes, or strategic initiatives included in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114974,"accession_number":"0001628280-26-012264","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Solutions Q4 2025 rev $24.8M (+20% YoY), GAAP net income $2.1M; guides 2026 rev $112.5-$115M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $24.8M (+20% YoY); full-year revenue $96.2M (+29% YoY).","GAAP net income Q4 $2.1M ($0.04 EPS) vs net loss $1.2M; adjusted EBITDA $6.9M (28% of revenue).","2026 guidance: revenue $112.5M-$115.0M (17-20% growth), full-year GAAP net income expected.","Biopreservation media in 16 approved CGT products; >70% share in Phase III CGT trials.","Divested evo in Oct 2025 for $25.5M cash; cash & securities $120.2M at Dec 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":96214000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114973,"accession_number":"0001628280-26-001767","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Solutions reports preliminary Q4 2025 revenue $24.8M (+20% YoY); FY 2025 revenue $96.2M beats raised guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 continuing ops revenue $24.8M, up 20% from $20.7M in Q4 2024.","FY 2025 revenue $96.2M, up 29% from $74.6M in 2024, exceeding raised guidance of $95-96M.","Q4 revenue excludes ~$1.3M in biopreservation revenue shifted to Q3 at customer request.","CEO notes evo divestiture complete; company now pure-play cell processing with recurring revenue.","Expects 2026 revenue growth and adjusted EBITDA margin expansion; full guidance in Feb."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":96214000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114972,"accession_number":"0001628280-26-001649","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioLife Solutions' Chief Quality and Operations Officer Karen Foster to retire effective March 31, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Karen Foster, Chief Quality and Operations Officer, notified retirement effective March 31, 2026.","Retirement is not due to any disagreement with the company on operations, policies, or practices.","No replacement or interim appointment has been announced at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131360,"accession_number":"0001628280-25-052479","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLife Solutions issues investor presentation; no new financial or operational details disclosed in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed an 8-K to furnish investor presentation dated November 17, 2025.","Presentation available on company website but full content not included in filing.","No specific earnings, guidance, or material events revealed in the 8-K text or provided exhibit excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131359,"accession_number":"0001628280-25-050163","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Q3 total rev $28.1M (+31% YoY); net income $0.6M; raises cell processing guidance to $93-94M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q3 revenue $28.1M (up 31% YoY); Cell Processing revenue $25.4M (up 33% YoY).","GAAP net income $0.6M vs loss $0.5M in Q3 2024; adjusted EBITDA $7.8M (28% of revenue).","Full-year Cell Processing revenue guidance raised to $93-94M (from $91-93M); total rev $95-96M excl. evo.","Completed sale of evo cold chain logistics on Oct 6 for $25.5M cash, streamlining to pure-play cell processing.","Cash and marketable securities $98.4M as of Sep 30; no evo proceeds included."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":77429000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147945,"accession_number":"0000834365-25-000018","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2025-08-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BioLife Solutions annual meeting: two directors face >40% withhold votes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees re-elected; Ellingson and Goswami each received >40% withhold votes (19.8M and 17.5M withheld, respectively).","Advisory say-on-pay approved with 38.4M for, 2.06M against, 84k abstain.","Ratification of Grant Thornton as auditor passed with 43.0M for, 11k against.","Total shares outstanding 47.8M, with 43.1M represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147944,"accession_number":"0000834365-25-000014","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Solutions Q2 revenue up 29%; raises FY2025 guidance to $100-103M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $25.4M (+29% YoY); Cell Processing revenue $23.0M (+28% YoY).","GAAP net loss $15.8M includes non-cash $15.5M IPR&D charge from PanTHERA acquisition.","Non-GAAP adjusted net income $0.5M vs. loss of $1.0M a year ago; adjusted EBITDA $6.1M (24% of revenue).","Raises FY2025 Cell Processing revenue guidance to $91-93M; total revenue guidance to $100-103M.","Biopreservation media embedded in 16 approved therapies; over 250 ongoing trials, including 30+ Phase III."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":49362000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166664,"accession_number":"0001628280-25-023798","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Solutions Q1 revenue up 30% YoY to $23.9M; net loss narrows to $0.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cell Processing revenue of $21.6M (+33% YoY), driven by biopreservation media demand from commercial therapies.","GAAP net loss from continuing ops of $0.4M vs. $3.2M loss in Q1 2024; adjusted EBITDA of $5.7M (24% of revenue).","FY 2025 revenue guidance reaffirmed at $95.5M-$99.0M, representing 16%-20% growth over 2024.","Completed acquisition of PanTHERA CryoSolutions on April 4, 2025, adding novel cryopreservation IRI technology.","Cash and marketable securities of $107.6M at quarter end; balance sheet supports organic and inorganic growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":23941000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184082,"accession_number":"0001628280-25-014541","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"BioLife appoints Cathy Coste to board as director and audit committee chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective March 18, 2025, Catherine Coste appointed to board, replacing Joydeep Goswami as audit committee chair.","Coste brings over 30 years at Deloitte as senior partner and life sciences industry leader.","She will serve until 2025 Annual Meeting and receive standard non-employee director compensation.","Board expanded to seven members; Coste independent under SEC and Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184081,"accession_number":"0001628280-25-009233","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Solutions Q4 revenue $22.7M (+31% YoY); guides 2025 up 16-20%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $22.7M (up 31% YoY); Cell Processing $20.3M (+37% YoY).","GAAP net loss from continuing ops $2.0M vs $7.2M YoY; adjusted EBITDA $4.0M (18% of revenue).","Completed sales of SciSafe and CBS in Nov 2024 for ~$79.1M total cash; cash and marketable securities $109.2M.","2025 revenue guidance $95.5-99.0M (growth 16-20%); Cell Processing $86.5-89.0M (growth 18-21%).","Cumulative 769 FDA Master File cross-references; biopreservation media in 17 approved cell/gene therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184080,"accession_number":"0001628280-25-001252","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Solutions Q4 preliminary revenue $22.7M, +31% YoY; cell processing beats FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 continuing ops revenue $22.7M (+31% YoY); cell processing $20.3M (+37% YoY, +7% sequentially).","FY2024 continuing ops revenue $82.3M (+8% YoY); cell processing $73.5M exceeded raised guidance of $72-73M.","Evo and Thaw platform revenue fell 14% YoY to $8.7M for FY2024; Q4 down 8%.","Company completed divestitures of freezer and biostorage businesses, sharpening focus on CGT market.","CEO cites momentum, fortified balance sheet; full 2024 results and 2025 outlook due in February earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":82254000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200686,"accession_number":"0001628280-24-052235","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"BioLife Solutions appoints Tony J. Hunt (Repligen Chairman) to board effective Jan 2, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tony J. Hunt, Executive Chairman of Repligen (Nasdaq: RGEN), appointed to BioLife board.","Appointment increases board size to six members; Hunt qualifies as independent under Nasdaq rules.","Hunt previously served as Repligen CEO (2015-2024) and President of Bioproduction at Life Technologies.","He will serve on the Audit Committee and receive standard non-employee director compensation.","Board cites Hunt's bioprocessing expertise to support BioLife's focus on cell and gene therapy tools."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200685,"accession_number":"0001628280-24-048673","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["1.01","2.01","9.01"],"status":"ready","headline":"BioLife Solutions sells CBS unit to Standex for $6.1M, records $2M in stock comp and $1.5M debt repayment","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold Custom Biogenic Systems (CBS) to Standex International for ~$6.1M; transaction closed Nov 14, 2024.","Incurred $2.0M compensation expense from accelerated share vesting for CBS employees; repaid ~$1.5M of CBS debt.","CBS results classified as discontinued operations; pro forma shows revenue reduction of ~$10.2M for 9mo 2024 and ~$13.6M for FY2023.","Pro forma combined with prior SciSafe sale yields continuing ops net income of $6.9M for 9mo 2024 vs historical net loss $32.6M.","Entered transition services agreement with CBS post-closing; two-year non-compete covenant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200684,"accession_number":"0001628280-24-047143","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Solutions Q3 revenue up 30% to $30.6M; raises Cell Processing guidance to $72-73M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $30.6M (+30% YoY); Cell Processing $19.0M (+43% YoY); adjusted EBITDA $6.1M (20% margin).","GAAP net loss from continuing ops $1.7M vs $15.8M YoY; adj. gross margin 54% (up from 44%).","Completed sale of SciSafe biostorage business for $73M cash on Nov 12, 2024.","FY2024 revenue guidance revised to $98-100M; Cell Processing raised to $72-73M (previously $70-71M).","Biostorage guidance cut to $26-27M due to SciSafe divestiture; management expects positive adjusted EBITDA for full year."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":85678000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200683,"accession_number":"0001628280-24-046909","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["1.01","2.01","5.03","9.01"],"status":"ready","headline":"BioLife Solutions sells SciSafe for $73M cash; closes Nov 12, 2024","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold all SciSafe shares to Subzero Purchaser Corp. for $73M; repaid $0.9M of SciSafe debt and paid $3.3M to waive earn-out rights.","Entered transition services agreement with SciSafe for up to 6 months post-close.","Amended SVB loan agreement; added $750K non-refundable termination fee upon early loan termination.","Amended bylaws: quorum reduced to one-third voting power; added exclusive forum for derivative/Securities Act claims.","Pro forma shows continuing ops net income of $9.5M for H1 2024 vs. historical loss of $11.4M; net loss per share improved to $(0.22)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216696,"accession_number":"0001628280-24-036343","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K/A","filed_at":"2024-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Solutions corrects Q2 earnings; raises full-year revenue guidance to $99-101M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $28.3M, down 3% YoY but up 6% sequentially; Cell Processing up 11% sequentially.","GAAP net loss from continuing ops $7.1M (incl $4.1M write-off) versus $5.5M loss a year ago.","Non-GAAP adjusted EBITDA $4.8M or 17% of revenue, up from $1.7M or 6% in Q2 2023.","FY 2024 total revenue guidance raised to $99-101M; Cell Processing guidance raised to $70-71M.","8-K/A corrects prior release to reduce stock compensation by $2.1M from discontinued operations."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":55107000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216698,"accession_number":"0001628280-24-036163","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Q2 revenue $28.3M (-3% YoY), net loss $7.1M; raises FY24 revenue guidance to $99-101M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $28.3M (-3% YoY, +6% seq); Cell Processing $18.0M (+11% seq).","GAAP net loss from cont. ops $7.1M (incl $4.1M iVexSol write-off) vs $5.5M loss YoY; adj net loss $2.3M.","GAAP gross margin 51% vs 35% YoY; non-GAAP adj gross margin 52% vs 45%.","Adjusted EBITDA $4.8M (17% rev) vs $1.7M (6%) YoY.","Raises FY2024 revenue guidance to $99-101M from $95.5-100M; Cell Processing to $70-71M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":55107000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216697,"accession_number":"0001628280-24-035254","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BioLife Solutions stockholders re-elect five directors, approve say-on-pay, ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Roderick de Greef, Joydeep Goswami, Amy DuRoss, Rachel Ellingson, and Timothy Moore re-elected as directors.","Advisory vote on named executive officer compensation approved with 32.5M shares for, 5.0M against.","Ratification of Grant Thornton LLP as independent auditor for 2024 approved with 41.6M shares for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236373,"accession_number":"0001628280-24-022218","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Q1 net loss $10.2M; revenue down 16% YoY; divests GCI freezer unit, reaffirms 2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 total revenue $31.7M (-16% YoY); Cell Processing $16.2M (+10% seq), Biostorage $7.1M (+25% YoY), Freezers $8.4M (-35% YoY).","GAAP net loss $10.2M ($0.22 loss per share); adjusted EBITDA -$1.2M; pro forma ex-GCI adj. EBITDA +$3.6M (13% of revenue).","Closed sale of GCI freezer business Apr 17; funded $4.9M cash into GCI and repaid $2.6M debt to facilitate transaction.","Affirms FY24 revenue guidance $95.5M-$100.0M (ex-freezers); expects full-year positive adjusted EBITDA."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":31727000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236372,"accession_number":"0001628280-24-017460","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2024-04-23T23:59:59+00:00","items":["1.01","2.01","9.01"],"status":"ready","headline":"BioLife Solutions sells Global Cooling for $1, incurs ~$7.4M cash outflows","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold Global Cooling for $1.00; provided $4.9M to meet $7M cash closing condition.","Repaid $2.6M of Global Cooling’s term loan and assumed $1.8M in accounts payable.","Pro forma 2023 revenue drops to $107M from $143M; net loss improves from $66.4M to $57.9M.","Recorded $8.3M pro forma loss on sale; $2.5M RIF costs and $4.5M stock acceleration charges.","SVB consented, released liens on Global Cooling assets; $500K termination fee added to loan agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236371,"accession_number":"0001628280-24-016671","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2024-04-18T23:59:59+00:00","items":["2.05","8.01","9.01"],"status":"ready","headline":"BioLife Solutions divests Stirling freezer business for $1; cuts 11% of workforce","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold Global Cooling (Stirling) for $1.00; expects to eliminate several million dollars of quarterly cash burn.","Workforce reduction of 47 employees (~11% of full-time); estimated $2.5M charges in Q2 2024.","Removes $7.5M warranty liabilities; $7M cash left in GCI and $2.6M debt repayment.","Expects higher revenue growth, adjusted EBITDA, and gross margin expansion after sale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254035,"accession_number":"0001628280-24-007964","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Q4 rev $32.7M (-26% YoY); guides 2024 rev $95.5-100M ex-freezer; adj EBITDA positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP net loss $13.4M ($0.30 loss/share) vs $49.2M loss ($1.15) in Q4 2022.","Cell Processing platform Q4 rev $14.8M, down 27% YoY but up 11% sequentially.","Freezer divestiture underway; expects sale by end of Q1 2024.","2024 revenue guidance $95.5-100.0M (ex-freezer); expects full-year positive adjusted EBITDA.","Biopreservation media embedded in 14 approved CGT therapies as of Feb 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":143271000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}